PTC Therapeutics (PTCT) Posts Q4 Loss of 84c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
PTC Therapeutics (PTCT) Target Lifted to $81 at Wedbush
March 2, 2015 12:52 PM ESTWedbush analyst Heather Behanna reiterated an Outperform rating and boosted her price target on PTC Therapeutics (NASDAQ: PTCT) to $81.00 (from $68.00), noting the Translarna launch is off to a good start.
Behanna commented, "A combination of commercial launch in Germany and reimbursed expanded access... More
PTC Therapeutics (PTCT) PT Raised on BofA/Merrill Lynch on ex-US Translarna Sales
March 2, 2015 8:07 AM ESTBofA/Merrill Lynch analyst Tazeen Ahmad reiterated a Buy rating and boosted its price target on PTC Therapeutics (NASDAQ: PTCT) to $87.00 (from $60.00) following Q4 results and ex-US Translarna sales.
Ahmad notes that on the call PTC reported early ex-US launch metrics for its... More



